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ABSTRACT 
There is limited evidence indicating that drug-eluting dressings are clinically more effective 
than simple conventional dressings. To shed light on this concern, we have performed 
evidence-based research to evaluate the antimicrobial action of thymol (THY)-loaded 
antimicrobial dressings having antibiofilm forming ability able to eradicate intracellular and 
extracellular pathogenic bacteria. We have used four different Staphylococcus aureus strains, 
including the ATCC 25923 strain, the Newman strain (methicillin-sensitive strain, MSSA) 
expressing the coral green fluorescent protein (cGFP) from the vector pCN47, and two 
clinical reference strains, Newman-(MSSA) and USA300-(methicillin-resistant strain, 
MRSA), as traceable models of pathogenic bacteria commonly infecting skin and soft tissue. 
Compared to non-loaded dressings, THY-loaded polycaprolactone based electrospun 
dressings were also able to eliminate pathogenic bacteria in coculture models based on 
infected murine macrophages. In addition, by using confocal microscopy and the 
conventional microdilution plating method, we corroborated the successful ability of THY 
in preventing also biofilm formation. Herein, we demonstrated that the use of wound 
dressings loaded with the natural monoterpenoid phenol derivative THY are able to eliminate 
biofilm forming and intracellular S. aureus sensitive to methicillin more efficiently than their 
corresponding THY-free counterparts.  
 
KEYWORDS: electrospinning, polycaprolactone, essential oils, infection model, confocal 
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1. INTRODUCTION  1 
In 1945, Sir Alexander Fleming claimed that the overuse of antibiotics leads to the evolution 2 
of resistance.1,2 Different studies show that there is a direct relationship between antibiotic 3 
consumption and the diffusion of resistant bacterial strains.3 Approximately, 80% of 4 
antibiotics sold in U.S.A. are administered to animals, which are lately ingested by humans.2,4 5 
Besides animal feeding, 30 to 60 % of antibiotics are also incorrectly prescribed, which leads 6 
to therapeutic complications and a potential increase of antibiotic resistance.5 The economics 7 
in the search of new antibiotic molecules might not justify the necessary investment for the 8 
pharmaceutical industry.6  In addition, despite all the global efforts to control and reduce the 9 
use and misuse of antibiotics, a retrospective report has recently demonstrated that the 10 
antibiotic use in 76 countries studied over 16 years (2000-2015) increased 65% (expressed 11 
as prescribed daily doses), and the antibiotic consumption rate increased 39%.7 Thus, new 12 
alternatives have been developed to treat bacterial infections. For example, natural 13 
compounds and metal nanoparticles are proposed as antibiotic substitutes due to their 14 
multiple mechanisms of antimicrobial action.8 The probability to develop bacterial resistance 15 
towards essential oils (EOs) is low. This fact may fall on the multicomponent nature and 16 
varied composition of EOs and in their ability to target multiple antibacterial pathways, 17 
meanwhile antibiotics normally focus on only one single target.9 However, it has been 18 
reported that bacteria can modify its membrane composition and structure in response to 19 
subinhibitory concentrations of some antimicrobials present in EOs such as thymol (THY).10 20 
Therefore, sustained concentrations above minimal inhibitory concentrations should be 21 
maintained at all times to prevent resistances.  22 
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THY, a monoterpenoid phenol compound present in different EOs as that obtained from 23 
Thymus vulgaris, has demonstrated its antimicrobial activity against different bacterial 24 
strains such as Staphylococcus aureus, a major human pathogen which causes substantial 25 
morbidity and mortality in skin and soft tissue associated infections as well as in implant-26 
associated infections.11–13     27 
To overcome EOs solubility limitations and provide with sustained release, new 28 
pharmaceutical formulations have been proposed.14 Nanotechnology has contributed to the 29 
development in different areas of medicine including diagnosis, therapy and in their 30 
combination (i.e., theragnostics).15 Within the nanotechnology field, due to their large area 31 
per volume ratio, nanofibers outstand as ideal building blocks in different biomedical 32 
materials applied in drug delivery,16 biomedical devices,17 biosensing18 or as dressings for 33 
wound healing.19 Regarding this last application, the synthesis of polymeric electrospun 34 
nanofibers loading antimicrobial and anti-inflammatory drugs (including EOs), has been 35 
explored in the development of antimicrobial wound dressings.20 In contrast to conventional 36 
fibers, nanofibrous patches contain fibers ranging from nanometers to micrometers showing 37 
high porosity, narrow diameter distribution and high-specific surface area prone to the release 38 
of loaded antimicrobial compounds. Some electrospun dressings are made of biomaterials 39 
recognized for their biocompatibility, biodegradability and lack of toxicity, such as natural 40 
or synthetic polymers (chitosan, collagen, polycaprolactone (PCL) or poly lactic-co-glycolic 41 
acid (PLGA)).21 PCL is a biocompatible polymer approved by the FDA in many devices due 42 
to its high biocompatibility and controlled hydrolytic biodegradation.22 Loaded with 43 
antimicrobial drugs, PCL nanofibers have demonstrated high efficiency not only preventing 44 
infection development, but also avoiding biofilm formation.23–25  45 
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Biofilms are populations of microorganisms aggregated and embedded in an organic self-46 
secreted extracellular matrix made of polysaccharides (EPS) which provides bacteria with a 47 
protective environment to medical treatments. It is well known that bacteria on chronic 48 
infected wounds do not remain in their free-living planktonic state but organized as 49 
biofilms.26 Within the biofilm, there are intercellular signaling molecules produced by 50 
bacteria that respond to cell population density by gene regulation. In response to factors 51 
secreted by other bacteria in the community, bacteria can coordinate their activities, control 52 
the biofilm growth pattern or change their phenotype and thus, their virulence factors.27 53 
Antibiotics can penetrate the extracellular surface of planktonic bacteria, but bacteria within 54 
the biofilm can be protected and the antibiotic diffusion impaired.28 Against this fact, EOs 55 
have been studied for their biofilm disruption potential. It has been reported the ability of 56 
some EOs to inhibit biofilm formation or disrupt already formed biofilms, suggesting their 57 
potential use in food preservation and in antimicrobial therapies.29,30 Their antibiofilm 58 
activity may be attributed to different mechanisms: the inhibition of bacterial adhesion to 59 
surfaces at an initial stage, or the inhibition of Quorum Sensing (cell to cell 60 
communication).30 THY has been shown as an effective compound to inhibit biofilm 61 
formation, not only in monomicrobial cultures of S. aureus, but also in polymicrobial cultures 62 
of different bacteria (e.g., S. aureus, Listeria monocytogenes).12,29 This effect may be 63 
attributed to the disruption of bacteria membrane permeability and thus, hindering surface 64 
adhesion.31 Therefore, THY reduces bacterial growth, interferes with biofilm formation and 65 
promotes biofilm eradication.32   66 
Exposed subcutaneous tissues have been shown as critical scenarios for potential infection 67 
development facilitating a suitable microenvironment for bacteria colonization and 68 
contamination.33 The risk of infection represents a general concern in skin and soft tissue 69 
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open wounds, where each phase of wound healing is challenged by the possibility of 70 
microbial infection.34,35 Following postsurgical wound analysis, it has been demonstrated that 71 
the average hospitalization period rises from 14 to 24 days when wounds become infected.36 72 
Infected wounds are characterized by a failure in the inflammation, re-epithelialization and 73 
remodeling phases. The most representative signs of infection are pain, erythema, edema, 74 
heat and purulence, exudate, discoloration or wound breakdown.37 75 
For a successful tissue regeneration, the wound healing process requires the complete 76 
removal of any microbial exogenous contamination. Macrophages play an essential role in 77 
wound healing, not only eliminating pathogens or dead cells, but also releasing cytokines, 78 
growth and angiogenic factors that take part in the wound healing process.38 In this regard, 79 
tissue-resident macrophages recognize pathogen-associated patterns, such as the presence of 80 
bacterial endotoxin lipopolysachharide (LPS) during infection, recruiting other cells which 81 
help fighting a potential infection.39 S. aureus is a pathogen described to survive within 82 
phagocytic cells, such as macrophages, persisting in parts of its life-cycle intracellularly 83 
during infections.13,40,41 Co-culture models of S. aureus infected macrophages have been 84 
developed to study the behavior of bacteria under the presence of different antimicrobial 85 
treatments.41–43 86 
Herein, we have developed electrospun THY-loaded PCL nanofibers and we have studied 87 
the effect of these advanced drug-eluting wound dressings against different S. aureus strains: 88 
ATCC 25923 strain, GFP-expressing antibiotic sensitive S. aureus (MSSA) growth, and two 89 
clinical reference strains, Newman-(MSSA) and USA300-(methicillin-resistant strain, 90 
MRSA). Three different infection models have been developed: (a) planktonic bacteria, (b) 91 
biofilm formation and (c) a co-culture model of J774 macrophages infected with GFP-92 
expressing S. aureus. Besides the development of quantitative methods, confocal microscopy 93 
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was used to observe both biofilm formation and bacteria eradication in the co-culture model 94 
after treatment with different dressings based on THY-loaded PCL nanofibers.  95 
 96 
2. EXPERIMENTAL SECTION 97 
2.1. Materials 98 
PCL (Mn = 80,000 Da), (S)-(-)-limonene (food grade, ≥95%), naproxen sodium salt (98–99 
102%), phosphate buffered saline (PBS), thymol (THY, >98.5%), Erythromycin, Bovine 100 
Serum Albumin (BSA), Calcofluor White stain and CellCrown™ inserts (24-well plate 101 
inserts) were purchased from Sigma-Aldrich (Germany). Dichloromethane (DCM, >99%), 102 
N,N-dimethylformamide (DMF, >99%), Phalloidin 546 and DAPI were obtained from Fisher 103 
Scientific (USA). Tryptone soy broth (TSB) and tryptone soy agar (TSA) were purchased 104 
from Laboratorios Conda-Pronadisa S.A. (Spain). S. aureus ATCC 25923 strain was 105 
obtained from Ielab (Spain), while GFP-expressing antibiotic sensitive S. aureus (MSSA) 106 
and the two clinical strains Newman-(MSSA) and USA300-(MRSA) were kindly donated by 107 
Dr. Cristina Prat, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP, 108 
Spain). Paraformaldehyde (PFA) 4% in PBS was acquired from Alfa Aesar (Germany). 109 
Saponin from Quillaja Bark pure and SDS for molecular biology were purchased from 110 
AppliChem (Germany). Fetal Bovine Serum (FBS) was obtained from Gibco (UK) while 111 
penicillin-streptomycin-amphotericin B (PSA) was purchased from Biowest (France) and 112 
Dimethyl sulfoxide (DMSO) from Merck Millipore (Germany). MTT (3-(4,5-113 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was obtained from Invitrogen 114 
(USA). 115 
2.2. Preparation of PCL and THY-loaded PCL nanofibers  116 
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A solution of PCL (10 w/w %) was prepared in dichloromethane (DCM) and 117 
dimethylformamide (DMF) at 1:1 volume ratio. For the preparation of THY-loaded PCL 118 
nanofibers, THY was added to the polymeric solution at 20 w/w % concentration (referred 119 
to the PCL mass). The mixture was stirred for 30 min before electrospinning.  120 
An Yflow 2.2 D500 electrospinner equipped with a rotating drum collector (100 rpm) was 121 
used to obtain bare and THY-loaded PCL-nanofibers. The collection drum was covered with 122 
aluminum foil to facilitate the recovery of the electrospun nanofibers. PCL and PCL-THY 123 
solutions were electrospun through a 22-gauge needle with a syringe pump working at 1.0 124 
mL/h flow rate. The distance from the tip of the needle to the collector was 18 cm. The 125 
voltage applied to the collector plate was -7 kV and the voltage applied to the needle was 126 
+10 kV with the aim of obtaining a stable Taylor cone. Homogeneous patches of bare and 127 
THY-loaded PCL nanofibers were obtained after 8h of electrospinning. 128 
2.3. Physico-chemical characterization of the electrospun nanofibers 129 
The resulting electrospun patches were observed by scanning electron microscopy (SEM) 130 
using an Inspect F50 SEM microscope. Samples were covered with an Au/Pd layer before 131 
electronic visualization. Resulting images were analyzed and nanofiber sizes measured (N = 132 
100) using the ImageJ software (Version 1.48f, NIH, USA).   133 
THY loading in the fibers was determined by GC-MS using a Shimadzu 2010SE GC-MS 134 
chromatograph equipped with an AOC 20i injector and a Zebron ZB-50 capillary column (30 135 
m x 0.25 mm, 0.25 µm thickness, Phenomenex). Ten mg of nanofibers were dissolved in 136 
DCM:acetonitrile (1:1), each sample was diluted with known amounts of methanol and 5 137 
ppm of (S)-(-)-limonene that was added as internal standard. Helium was used as carrier gas. 138 
Drug loading (DL) was calculated using Eq.1:  139 
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𝐷𝐿 %  
𝑊𝑒
𝑊𝑛
 𝑥 100 140 
Encapsulation efficiency (EE) was calculated following Eq. 2: 141 
𝐸𝐸 %  
𝑊𝑒
𝑊𝑡
 𝑥 100 142 
Being Wt the theoretical THY load added, We the measured THY load chromatographically 143 
quantified and Wn the total weight of the THY-loaded nanofibers. 144 
2.4. Release of THY 145 
THY release was carried out under temperature-controlled conditions using an IKA® KS 130 146 
orbital shaker. Ten mg of PCL-THY patches were immersed in 4 mL of PBS and kept at 37 147 
ºC under stirring (150 rpm). At different time points up to 24h, the supernatant from 148 
independent samples at each time was collected and analyzed in an Acquity UPLC® Waters 149 
liquid chromatography system and Waters® Empower™ chromatographic software (Waters, 150 
USA). An Acquity UPLC® Waters BEH C18 column (2.1 x 50 mm, 1.7 µm particle 151 
diameter) was employed for the analysis of THY. In the determination, 25 ppm of naproxen 152 
was included as internal standard.  153 
The release kinetics were determined by fitting the data through the Peppas-Sahlin model. 154 
The correlation coefficient (R2) value was calculated from the linear regression of these plots 155 
following this equation (Eq. 3): 156 
𝑀
𝑀
𝐾 𝑡 𝐾 𝑡  157 
where Mt/MT is the drug release fraction at time t, K1 and K2 are constants and N is the 158 
diffusional exponent. 159 
2.5. Viscosity and conductivity measures  160 
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Relative viscosity of precursor solutions was measured at 25 ºC using a Visco Basic Plus 161 
viscosimeter (Visco Basic, Spain). Solutions conductivity was measured with a multimeter 162 
MM41-Criston (Hach Lange, USA).   163 
2.6. Bactericidal activity  164 
Antibacterial activity was determined in a methicillin-sensitive S. aureus Newman strain 165 
expressing the coral green fluorescent protein (cGFP) from the vector pCN47. Minimal 166 
inhibitory (MIC) and bactericidal (MBC) concentrations were tested following the standard 167 
microdilution method.44 Different concentrations of free THY (0.01-0.15 mg/mL) were 168 
analyzed in liquid growth medium (TSB) and THY-loaded PCL nanofibers were studied in 169 
agar broth (TSA) according to the ASTM E-2180-18 standard test method.45 A positive 170 
control (untreated bacteria) was also included in both methods.  171 
To assess inhibitory and bactericidal effects of free THY on cGFP expressing S. aureus 172 
cultures, a 20 mg/mL stock solution of THY in DMSO and diluted in TSB up to reach study 173 
concentrations was prepared. A solution of 105 Colony Forming Units (CFU)/mL of bacteria 174 
was added to different free THY concentrations and incubated for 24h at 37 ºC under shaking 175 
(150 rpm). After this time, bacterial suspensions were diluted in PBS and plated on TSA to 176 
count colonies after 24h of incubation at 37 ºC.  177 
Separately, patches composed of THY loaded nanofibers were cut, weighted and sterilized 178 
using UV light (30 min each side). Warm TSA (47 ºC) was inoculated with 105 CFU/mL of 179 
cGFP expressing S. aureus. Nanofiber-based patches were placed in 12-well plates and 3 mL 180 
of inoculated TSA were added to each well. Samples were incubated at 37 ºC for 24h in a 181 
closed box with water to keep an adequate humidity. After incubation, each sample was 182 
collected with 7 mL of TSB, sonicated and vortexed for 1 min. Bacterial suspensions were 183 
diluted in PBS and plated on TSA to count colonies after 24h of incubation at 37 ºC. 184 
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2.7. Antibiofilm activity 185 
Four S. aureus strains (ATCC 25923, GFP-expressing antibiotic sensitive S. aureus (MSSA) 186 
growth, and the two clinical reference strains Newman-(MSSA) and USA300-(MRSA) were 187 
overnight cultured until reaching stationary phase. To evaluate the effect of PCL-THY 188 
against biofilm formation, two different procedures with varied PCL-THY masses and 189 
incubation times were carried out in µ-dish 35 mm ibiTreat plates:  190 
- In the first methodology, 104 CFU/mL of bacteria were put in contact with 5 and 7 191 
mg of PCL-THY patches and incubated for 24h at 37 ºC.  192 
- In the second approach, bacteria in the exponential growth phase (104 CFU/mL) were 193 
separately prepared and 10 and 12 mg of PCL-THY patches were added to the culture 194 
and incubated for 1h. Later, patches were removed, and culture media was kept at 37 195 
ºC for 24h.  196 
These parameters were chosen as a result of the bactericidal effects and cell viability 197 
percentages obtained in order to use PCL-THY amounts able to eradicate bacteria but 198 
harmless to eukaryotic cells. 199 
After incubation, both approaches were processed simultaneously. Planktonic cells were 200 
removed, and wells were washed twice with PBS. Biofilm formation was analyzed by 201 
following two different methods in which THY-free patches (composed of just PCL) were 202 
tested as controls: 203 
- For confocal microscopy, the biofilm matrix was treated for 1 min with Calcofluor 204 
White stain and washed with PBS. Next, 2 mL of PFA 4% in PBS were added to each 205 
plate. After 30 min incubation, samples were mounted in Mowiol mounting medium 206 
(Thermo Fisher Scientific, USA) to be further visualized by confocal microscopy 207 
(Confocal Zeiss LSM 880 with Airyscan).  208 
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- For bacteria quantification, biofilm in PBS was sonicated for 15 min in an ultrasonic 209 
water bath to ensure its detachment from the bottom of the wells. Later, detached 210 
bacteria concentrations were tested following the conventional microdilution 211 
method44 to be then plated on TSA and colonies counted after incubation (24h, 37 212 
ºC). 213 
2.8. Cell culture and cytotoxicity assays  214 
J774 macrophages were used to evaluate the cytotoxic effects of THY-loaded patches prior 215 
to their application in a co-culture model with GFP-expressing S. aureus. Macrophages were 216 
grown in high-glucose DMEM supplemented with 10% FBS and 1% PSA and incubated in 217 
a humidified atmosphere at 37 ºC and 5% CO2.  218 
Different amounts of PCL-THY were tested at different time points:  219 
- First, cells were seeded in 6-well plates (48000 cells/cm2), and 5 and 7 mg of PCL-220 
THY were added to the cultures (2 mL). Samples were incubated at 37 ºC, 5% CO2 221 
for 24h. Later, patches were removed, and cells were washed twice with PBS.  222 
- Another approach was followed using 10 and 12 mg of PCL-THY which were added 223 
to 2 mL of cell cultures (48000 cells/cm2) and incubated for 1h (37 ºC, 5% CO2). 224 
Later, these patches were removed, and cells were further incubated with 225 
supplemented DMEM at 37 ºC, 5% CO2 for 24h. Then, cells were washed twice with 226 
PBS.  227 
After cell treatment with the loaded patches following both approaches, the MTT cytotoxicity 228 
assay for assessing cell metabolic activity was used by preparing a stock solution of the 229 
tetrazolium dye at 5 mg/mL in PBS. Cells were incubated with 0.5 mg/ mL of the MTT dye 230 
for 3h at 37 ºC. After the incubation period, medium was removed, and the dye was 231 
solubilized with a solution containing DMSO (99.4% v/v), SDS (0.1% w/v) and acetic acid 232 
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(0.6% v/v) for 15 min. The dye is reduced forming an insoluble formazan salt when the 233 
metabolism of cells is active. This salt was dissolved to obtain a purple solution which was 234 
quantified at OD of 540 nm (Multimode Synergy HT Microplate Reader; Biotek, USA). 235 
Viability percentages were calculated dividing the OD of treated samples by the OD obtained 236 
from the positive control samples. Mean ± SD of three replicas are represented. 237 
2.9. In vitro model of infection of J774 macrophages 238 
J774 macrophages were seeded in µ-dish 35mm ibiTreat plates (130000 cells/cm2) overnight. 239 
Prior to the infection assays, supplemented DMEM containing antibiotics was removed, cells 240 
were washed twice with PBS and DMEM renewed without adding antibiotics in order to 241 
avoid hampering infection. Non-infected and infected cells without treatment were also run 242 
as control samples (data not shown). Equally, THY-free patches (PCL) were tested in the 243 
cultures to evaluate the treatment effect. Both methodologies described in the cell 244 
cytotoxicity section were followed according to the corresponding patches weight and the 245 
results obtained in the cytotoxicity assays to elucidate the efficiency of the patches related to 246 
their weight and thus, their THY loading. Patches were added to culture cells and then 247 
infected with 105 CFU/mL of GFP-expressing S. aureus in DMEM without antibiotics 248 
previously prepared. Treated cultures were incubated for 30 min (10 and 12 mg PCL-THY) 249 
or 24h (5-7 mg PCL-THY) at 37 ºC and 5% CO2. After those time periods, patches were 250 
removed, cells were washed twice with PBS and fixed in PFA 4% during 30 min at room 251 
temperature.  252 
Confocal microscopy was then used to monitor the effect of PCL-THY in the infection model 253 
of J774 macrophages by GFP-expressing S. aureus. After fixation, cells were first washed 254 
with PBS-BSA 1% and secondly, with saponin 0.1% in PBS-BSA solution. Straightaway, 255 
the plates were incubated in the dark with 500 µL of phalloidin 546 (1:200 in PBS-BSA-256 
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saponin prepared solution; Thermo Fisher Scientific, USA) for 1h at room temperature. After 257 
incubation, cells were rinsed with PBS-BSA 1% and then with distilled water. Finally, 258 
coverslips were mounted on glass slides in DAPI-Mowiol mounting medium (Thermo Fisher 259 
Scientific, USA). Samples were analyzed under confocal microscopy (Confocal Zeiss LSM 260 
880 with Airyscan). Z-stack orthogonal projections were used to visualize the presence of 261 
bacteria inside the eukaryotic cells.  262 
2.10. Statistical analyses 263 
All values are reported as Mean ± SD. Statistical analysis of data was performed using Prism 264 
7 software (Version 7.04, GraphPad Software Inc., US). Three replicas for each biological 265 
experiment were performed. A one-way analysis of variance (ANOVA) set for multiple 266 
comparisons with a Dunnett’s post-test was used. Statistically significant differences were 267 
considered when p ≤ 0.05. 268 
3. RESULTS AND DISCUSSION 269 
3.1. Physico-chemical characterization of the electrospun nanofibers 270 
Figure 1 shows SEM micrographs of PCL and THY-loaded PCL nanofibers. Both fibrous 271 
patches were homogeneous in their fiber diameter distribution having a bead-free surface. 272 
PCL patches showed mean fiber diameters of 779 ± 86 nm, meanwhile THY-loaded PCL 273 
nanofibers mean diameter was 794 ± 96 nm. Sadeghianmaryan et al.46 also obtained PCL 274 
nanofibers with a small dispersity in size and random orientation following the same 275 
methodology. 276 
The morphology and dimensions of the electrospun fibers depend on processing and polymer 277 
solution parameters.47 Synthesis parameters were the same for PCL and PCL-THY patches, 278 
using a polymer flow rate of 1 mL/h and a distance from the tip to the collector of 18 cm. 279 
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The presence of THY in the synthesis solution did not change the ionic conductivity (22.2 280 
S for PCL and 20.8 S for PCL-THY) and, despite of the increase in the solution viscosity 281 
(from 1.4 to 1.6 cP for PCL and for PCL-THY, respectively), it did not affect the resulting 282 
fibers morphology.47 In our case, the increase on the resulting fibers diameters compared to 283 
our previous results using similar experimental conditions19 would be related to the use of a 284 
rotating drum collector instead of a flat collector. Alfaro De Prá et al. also demonstrated that 285 
thicker PCL fibers with average diameters of 663 ± 334 nm can be obtained using a rotatory 286 
drum collector instead of a flat one.48 THY loading in the prepared fibers was 8.2 ± 0.9 wt.% 287 
which renders an encapsulation efficiency of 40.8 ± 4.6 wt.%. This low EE achieved could 288 
also be related to the use of a rotating collector, since for carvacrol (isomer of THY) loaded 289 
polyvinyl acetate fibers prepared using this collection system, the  EE was also low (43-55 290 
%) attributed to the evaporation of the monoterpenoid phenol derivative.49 The study of 291 
release kinetics demonstrated a fast THY release from the PCL-THY patches. Figure 1E 292 
shows that 30% of the encapsulated THY was released in the first hour. Peppas and Sahlin 293 
release kinetics model (Eq. 3) was the best mathematical fit for THY release showing a R2 294 
correlation coefficient of 0.993 (Figure 1E). This model describes a drug release occurring 295 
through the coupling of Fickian diffusion and polymer chains relaxation phenomena50. In our 296 
case the K1>>K2 implies that the Fickian diffusion is the predominant mechanism in the THY 297 
release.  298 
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Figure 1. Patches synthesis and characterization. (A) Scheme depicting the PCL nanofibers 300 
synthesis by electrospinning. (B) Table shows nanofiber diameters and PCL-THY drug 301 
loading (w/w %) and encapsulation efficiency (%). Mean ± SD (N=100). (C) PCL 302 
morphological characterization by SEM. (D) PCL-THY morphological characterization by 303 
SEM. (E) THY release and Peppas and Sahlin fitting parameters.  304 
 305 
3.2. Bactericidal activity 306 
Figure 2 shows the antibacterial activity of free and THY encapsulated PCL determined in 307 
cultures of GFP-expressing S. aureus. 0.05 mg/mL of free THY were enough to significantly 308 
inhibit bacteria growth, showing a reduction from 109 to 107 CFU/mL. When bacteria were 309 
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treated with 0.15 mg/mL of free THY, no growth was found, meaning that the MBC was 310 
reached. 311 
When bacteria were treated with PCL-THY, it was observed that 10 mg of PCL-THY reached 312 
the MIC inhibiting bacteria growth from 109 to 106 CFU/mL, whereas 12 mg of PCL-THY 313 
were enough to avoid GFP expressing-S. aureus growth (MBC) in an agar culture of 3 mL 314 
of volume containing an inoculum of 105 CFU. Considering THY loading and release 315 
kinetics from the patches, a mat of 10 mg would provide a THY concentration released of 316 
0.08 mg/mL in the analyzed time whereas 12 mg of PCL-THY would release THY to the 317 
medium reaching a THY concentration of 0.1 mg/mL. The slight MIC and MBC differences 318 
observed between free THY and THY released from the PCL-THY patches can be associated 319 
with the experimental method followed, since free THY is challenged against bacteria in a 320 
liquid culture medium (TSB), whereas THY-loaded patches were studied using solid agar 321 
(TSA).   322 
Wound healing may be impaired by wound infection mediated by different bacteria. The 323 
microorganisms closely related to the colonization of skin and soft tissue wounds are 324 
generally from the Staphylococci family (in particular, S. epidermidis and S. aureus).28 In 325 
previous studies, we have demonstrated that THY is one of the best natural compounds 326 
inhibiting bactericidal growth of S. aureus strains. Free THY showed a MIC of 0.2 mg/mL 327 
and a MBC of 0.3 mg/mL against a S. aureus ATCC 25923 strain.12 In the treatment with 328 
THY, Badawy et al.51 reported a MIC for ATCC 6538 S. aureus of 0.13 mg/mL, meanwhile 329 
Rua et al.52  identified a MIC in the range of 0.46-0.51 mg/mL for different S. aureus  strains. 330 
These previous studies point to the higher sensitivity of the GFP-expressing S. aureus strain 331 
used in this work since a concentration of 0.05 mg/mL of free THY was enough to inhibit 332 
the bacteria growth (MIC), whereas the complete elimination of the bacteria was reached 333 
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when free THY concentration was 0.15 mg/mL. Moreover, higher sensitivity of this strain 334 
was also found for THY loaded PCL fibers. The comparison of these results with our 335 
previous studies19 showed the same pattern. In the current study, 12 mg of THY-loaded PCL 336 
patches (corresponding with 0.1 mg/mL of THY released in 24h) were enough to achieve the 337 
MBC when working with GFP-expressing S. aureus, meanwhile 30 mg of PCL-THY (0.38 338 
mg/mL of THY released in 24h) were needed to completely eradicate bacteria using the S. 339 
aureus ATCC 25923 strain.19 These differences in THY susceptibility may be attributed to 340 
phenotypic differences among S. aureus strains as explained above. 341 
 342 
Figure 2. Effect of THY treatment in GFP-expressing S. aureus growth (CFU/mL) in contact 343 
for 24h. (A) Free THY (0.01-0.15 mg/mL). (B) PCL-THY (10-12 mg). All samples are 344 
statistically compared with the positive control sample (non-treated bacteria). *p<0.05; 345 
****p<0.0001. Mean ± SD of three replicas are represented.  346 
 347 
3.3. Antibiofilm activity 348 
GFP expressing-S. aureus biofilm formation was monitored by confocal microscopy by using 349 
the Calcofluor White stain (Figure 3). As mentioned in the experimental section, two 350 
approaches were followed based on the incubation times and the amount of THY-loaded PCL 351 
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patches used regarding the bactericidal effects and cell viability percentages obtained in order 352 
to use PCL-THY amounts able to eradicate bacteria but harmless to eukaryotic cells.  353 
As it can be observed in Figure 3, THY-free PCL (7 and 12 mg; left images) patches let 354 
bacteria (stained in green) grow all over the well, forming a homogeneous layer of biofilm, 355 
which was clearly stained with Calcofluor White (in blue) on top of the bacteria settled 356 
underneath (green layer), as depicted in the bottom panels of both images. These results 357 
suggest that bacteria released the polymeric extracellular material typical of biofilm on the 358 
wells. However, the loaded patches clearly decreased the amount of bacteria present in the 359 
wells showing lower bacteria density when the patch´s weight was increased. Right images 360 
clearly show that the presence of bacteria was almost totally eliminated when the THY 361 
concentration was increased. In this case, although all treated samples were stained with 362 
Calcofluor White, none of them showed a top coating labelled in blue which would be 363 
characteristic of biofilm formation, demonstrating the lack of biofilm formation and 364 
highlighting the ability of the loaded patches to avoid or eradicate biofilms.  365 
 366 
 367 
 368 
 369 
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 370 
 371 
Figure 3. Confocal laser scanning microscopy was performed to evaluate the effect of 372 
different THY-loaded patches having different weights (5-7 mg and 10-12 mg) and different 373 
incubation times (1h and 24h), regarding the bactericidal effects and cell viability percentages 374 
obtained, compared with PCL control samples. For each incubation time, the three upper 375 
images correspond to GFP-expressing S. aureus attached to the bottom of the well. Bottom 376 
images show the Calcofluor stain of biofilm formed. Bacteria are depicted in green whereas 377 
biofilm stains in blue.  378 
 379 
These qualitative results were confirmed with a quantitative method in which not only the 380 
GFP-expressing antibiotic sensitive S. aureus (MSSA) was assayed, but also other three 381 
strains were analyzed to corroborate the bactericidal potential of the synthesized mats: ATCC 382 
25923, and the two clinical reference strains Newman-(MSSA) and USA300-(MRSA). 383 
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Attached bacteria were collected from the bottom of the wells and cultured in agar plates. 384 
Figure 4 shows the bacteria growth quantification after treatment following both 385 
methodologies. Positive controls (7-30 mg of PCL patches) reached 109 CFU/mL of bacteria 386 
growth in 24h whereas the treatment with 5-7 mg of PCL-THY for 24h (Figure 4A) or with 387 
10-12 mg of PCL-THY for 1h (Figure 4B) displayed a significant decrease in bacterial 388 
growth in the range of 105-106 CFU/mL, confirming the qualitative results showed in Figure 389 
3.  S. aureus ATCC 25923 (Figure 4C) exerted a significant inhibition of bacteria growth 390 
(107 CFU/mL) when biofilm was treated with 10 mg of PCL-THY while the addition of 30 391 
mg of the mat were able to completely eliminate the biofilm. On the other hand, the clinical 392 
isolates Newman-MSSA (Figure 4D) and USA300-MRSA (Figure 4E) showed a significant 393 
decrease in bacteria proliferation at the highest mat weight assayed (30 mg) achieving 394 
bacteria growth of 104 and 108 CFU/mL, respectively, (whereas for the THY-free mats 395 
bacteria grew until reaching ~1010 CFU/mL), which are in accordance with their sensitive 396 
and resistant characteristics.  397 
Considering the release kinetics results, 5 and 7 mg of PCL-THY patches would release in 398 
24h 0.06 and 0.09 mg/mL of THY, respectively. These concentrations in which we obtained 399 
MIC values, correlate with the inhibitory concentrations when using free THY against 400 
planktonic bacteria. Those results highlight the potential of these patches to provide with 401 
prophylaxis against biofilm formation and to reduce already formed biofilms. 402 
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 403 
 404 
Figure 4:  Quantification of GFP-expressing S. aureus (Fig. 4A and 4B), S. aureus ATCC 405 
25923 (Fig. 4C), S. aureus Newman (MSSA clinical strain; Fig. 4D) and S. aureus USA300 406 
(MRSA clinical strain; Fig. 4E) to evaluate biofilm formation against different treatments 407 
with PCL-THY: (A) 5-7 mg for 24h; (B) 10-12 mg for 1h, (C, D and E), 10-30 mg PCL-408 
THY for 24h. Different THY-loaded patches of different weights (5-30 mg) and different 409 
incubation times (1h and 24h) were selected regarding the bactericidal effects and cell 410 
viability percentages obtained. Results derived from PCL-THY are statistically compared to 411 
those obtained from the THY-free PCL patches used as control. **p<0.01; ***p<0.001; 412 
****p<0.0001. Mean ± SD of three replicas are represented.  413 
 414 
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A recent study states that 78% of non-healing chronic wounds contain biofilms.34 The 415 
elimination of bacterial bioburden is essential to promote wound healing in chronic wounds.53 416 
Sharifi et al. demonstrated that sub-MIC concentrations (MIC/2 to MIC/16) of different EOs 417 
obtained from Thymus daenensis and Satureja hortensis in contact with S. aureus for 24h, 418 
significantly prevented biofilm formation.31 In this sense, Yuan et al. also showed the 419 
efficiency of free THY in the inhibition of biofilm obtained from the non-clinical MRSA 420 
strain TCH1516 (ATCC BAA-1717). Biofilm formation and mature biofilm were inhibited 421 
by the treatment with up to 512 µg/mL of free THY, a concentration much higher than those 422 
released from our mats, though not achieving the complete eradication of bacteria growth.54 423 
Moreover, Cabarkapa et al. treated bacteria (Salmonella Enteriditis) with sub-MIC (MIC/2-424 
MIC/4) concentrations of Origanum and Thymus essential oils as well as their active 425 
components carvacrol and THY, and results showed that biofilm formation was inhibited.32 426 
These studies corroborate our results, not only 7 mg of PCL-THY eliminate already formed 427 
biofilms, but also we demonstrate that the exposition to 5 mg PCL-THY for 24h, reduces 428 
bacterial attachment to the well. The obtained results may evidence that cell wall damage can 429 
negatively affect bacterial attachment as we previously described12, which, according to 430 
Kerekes et al.29 represents the first step in biofilm formation, followed by formation of 431 
microcolonies, maturation and cell dispersal.29,31,55 The effect of THY against bacterial 432 
adhesion has also been demonstrated by Yuan et al.54 when they analyzed PIA 433 
(Polysaccharide Intracellular Adhesion), a component involved in adhesion and aggregation. 434 
This component was reduced under the presence of THY and thus, bacteria could adhere to 435 
materials at the initial stage, but they were unable to form biofilms due to a reduced cell-to-436 
cell adhesion.54,56 Therefore, THY reduces bacterial growth, interferes with biofilm 437 
formation and promotes biofilm eradication.32   438 
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3.4. Cytotoxicity assessment of PCL-THY patches  439 
Cytotoxicity of PCL-THY was studied in J774 macrophages at cell metabolism level using 440 
the MTT reduction assay. This method depends on the cellular activity of viable cells by 441 
producing a colored solution.  Cells were exposed to different amounts of PCL-THY 442 
following the two methodologies described in the experimental section. The results obtained 443 
from both approaches were compared with cells treated with THY-free PCL patches (control 444 
samples).  445 
In the first approach, cells were treated with 5 and 7 mg of PCL-THY for 24h. As depicted 446 
in Figure 5, a 50% cell growth inhibition was attained with 7 mg of PCL-THY, which 447 
corresponds to 0.09 mg/mL of THY released. However, the treatment with 5 mg of PCL-448 
THY (0.06 mg/mL of THY released in 24h) displayed a 80% cell viability after 24h 449 
incubation, classifying the material as non-cytotoxic (according to the value established by 450 
the ISO 10993-5).57  451 
Considering the direct relationship among increased concentration and cell toxicity, the 452 
treatment with more than 7 mg of PCL-THY for 24h would reduced significantly cell 453 
viability at levels below 70%. Due to that fact and keeping in mind that inhibitory and 454 
bactericidal concentrations were achieved with 10 and 12 mg PCL-THY, cells were treated 455 
with 10 and 12 mg PCL-THY but for a reduced incubation time (just 1h). Following this 456 
protocol, cell viability was quite similar for the mats weights evaluated, obtaining >70% of 457 
viability required to consider these concentrations as non-cytotoxic, which corresponds to 458 
0.12 mg/mL using 10 mg PCL-THY and 0.14 mg/mL using 12 mg PCL-THY for 1h.  459 
The cytotoxicity caused by THY against eukaryotic cells is related to its non-selective 460 
antiseptic character. During the regenerative process in an infected wound after adding an 461 
antiseptic, pathogenic prokaryotic cells are removed but also some somatic eukaryotic ones. 462 
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However, due to the immune response, new regenerative cells are recruited to the wounded 463 
area compensating the initial loss owing to the antiseptic effect. In addition, short contact 464 
times would minimize this cytotoxic effect. 465 
 466 
 467 
 468 
 469 
 470 
 471 
 472 
 473 
 474 
Figure 5. J774 macrophages viability after treatment with PCL-THY following two different 475 
approaches regarding the patch weight and incubation times in accordance with the 476 
bactericidal effects and cell viability percentages obtained: (A) Treatment for 24h (5 and 7 477 
mg of PCL-THY); (B) Treatment for 1h and incubation for other 24h (10 and 12 mg PCL-478 
THY). The results are graphed in basis to untreated cells which were assigned with a 100% 479 
viability. *p<0.05; **p<0.01; ****p<0.0001. Mean ± SD of three replicas are represented. 480 
  481 
3.5. In vitro model of infection of J774 macrophages 482 
We previously visualized the effect of PCL-THY on bacteria growth and biofilm formation. 483 
As we mentioned before, macrophages play a crucial role in wound healing, managing 484 
pathogens, phagocytizing dead cells and recruiting other cells which help to fight infection, 485 
such as neutrophils, fibroblasts, keratinocytes or endothelial cells.38,39 To investigate the 486 
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impact of the treatment of PCL-THY on a S. aureus infected cell line, J774 macrophages 487 
were visualized in contact with GFP-expressing S. aureus. Figures 6 and 7 represent the 488 
orthogonal projection using the maximum intensity projection (MIP), to visualize bacteria 489 
inside and outside cells, represented both in the same plane. Bacteria are shown in green 490 
while cell nuclei are stained with DAPI (blue) and cytoskeleton, with phalloidin 546 (red). 491 
Figure 6 depicts activated macrophages with LPS and treated with 5 and 7 mg of PCL-THY 492 
for 24h. Control samples (Figures 6A and 6B) showed cells totally filled with bacteria 493 
(green), indicating the successful infection of macrophages. However, the treatment with 5 494 
mg of PCL-THY (Figures 6C and 6D) and 7 mg of PCL-THY (Figures 6E and 6F) for 24h 495 
clearly demonstrated the efficiency of the synthesized loaded antimicrobial patches showing 496 
a reduced number of bacteria in a dose-dependent manner. In the time span studied, 5 and 7 497 
mg patches would release in 24h an amount of THY of 0.06 mg/mL and 0.09 mg/mL to the 498 
medium, respectively, concentration with which bacterial inhibition was detected.  499 
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 516 
Figure 6. In vitro co-culture model of GFP-expressing S. aureus and J774 macrophages. 517 
Cells were treated for 24h with: (A, B) 7 mg of PCL patches (control samples); (C, D) 5 mg 518 
PCL-THY; (E, F) 7 mg PCL-THY. Left images were acquired with a 63x oil immersion 519 
objective. Right images correspond with a zoomed area of left images. Bacteria are stained 520 
in green while cell nuclei are stained with DAPI (blue) and cytoskeleton with phalloidin 546 521 
(red). 522 
 523 
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Due to the results obtained in the cell toxicity study, infected macrophages were also treated 524 
with 10 and 12 mg PCL-THY though reducing the incubation time to 1h (Figure 7). These 525 
images demonstrated the same trend observed in the previous assay. When cells were treated 526 
with 12 mg of THY-free PCL (Figures 7A and 7B), bacteria were found throughout the plate. 527 
However, when cells were treated with 10 mg PCL-THY (0.12 mg/mL of THY released in 528 
1h; Figures 7C and 7D) and 12 mg PCL-THY (0.14 mg/mL of THY released in 1h; Figures 529 
7E and 7F) for 1h, bacteria concentration was significantly reduced, even totally when using 530 
the highest amount, confirming the efficiency of the fabricated PCL-THY mats in an in vitro 531 
infection model, pointing to their potential antibacterial application.  532 
  533 
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 551 
Figure 7. In vitro co-culture model of GFP-expressing S. aureus and J774 macrophages. 552 
Cells were treated for 24h with: (A, B) 12 mg of THY-free PCL; (C, D) 10 mg of PCL-THY; 553 
(E, F) 12 mg of PCL-THY. Left images were acquired with a 63x oil immersion objective. 554 
Right images correspond to a zoomed area of left images. Bacteria are stained in green while 555 
cell nuclei are stained with DAPI (blue) and cytoskeleton with phalloidin 546 (red). 556 
 557 
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Among other functions, biofilm allows bacteria to defense itself from external threats. Thus, 558 
immune cells are not able to reach and eliminate bacteria, and therefore a persistent 559 
inflammation and wound chronification occur.58 S. aureus may survive within phagocytic 560 
cells including macrophages, even when the host defense is activated.59 Based on that, GFP-561 
expressing S. aureus was chosen as a model of a bacterial pathogen with part of its life cycle 562 
occurring intracellularly to study and visualize the effect of PCL-THY on J774 macrophages 563 
in a co-culture infection model. The treatment of GFP-expressing S. aureus for 24h with a 564 
sub-inhibitory concentration (7 mg of PCL-THY, 0.09 mg/mL THY released) was found as 565 
cytotoxic to macrophages. It is not the first time that a high toxicity of THY is reported in 566 
eukaryotic cell cultures. For example, Belato et al. analyzed the cytotoxicity of free THY on 567 
murine macrophages (RAW 264.7) and showed that cell viability dropped from 75% to 5% 568 
at concentrations higher than 0.005 mg/mL.60 Prior studies of our group revealed a similar 569 
toxicity, obtaining a viability of 60% when J774 macrophages were treated with 0.12 mg/mL 570 
of free THY.61 The toxicity mechanism of this compound is poorly understood. There are 571 
different hypothesis about this issue; Gutierrez et al. reported that THY can affect the 572 
integrity of membranes in both prokaryotic and eukaryotic cells.62 However, Satooka et al. 573 
proposed that THY is intracellular transformed to a toxic radical and quinone, relating its 574 
toxicity to the oxidative-stress generated.63  575 
Compared with bactericidal planktonic studies, when J774 macrophages were infected with 576 
GFP-expressing S. aureus, it has been shown that a lower dose of PCL-THY patches is able 577 
to fight cell infection. That is probably because THY may help macrophages to control the 578 
progression of the infection in vitro.64 In summary, PCL-THY patches have demonstrated to 579 
induce a significant reduction of GFP-expressing S. aureus into infected J774 macrophages, 580 
diminishing their intracellular colonization. In addition, the ability of THY to reduce biofilm 581 
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formation, opens the possibility to fight bacterial infections and make the recovery of wound 582 
healing more efficient when using this locally delivery system based on thymol. 583 
 584 
4. CONCLUSIONS 585 
By comparing THY-free PCL electrospun patches as a model of a conventional wound 586 
dressing and THY-eluting PCL electrospun patches, the later outstand as efficient 587 
antimicrobial materials against pathogenic Gram-positive bacteria sensitive strains to 588 
conventional antibiotics (ATCC 25923 strain, MSSA Newman strain expressing cGFP, 589 
MSSA clinical strain), and in a lower extent to the MRSA clinical strain USA300. Moreover, 590 
a fluorescent bacteria was also used to demonstrate the successful infective action of the 591 
pathogen in eukaryotic cells as a model of intracellular pathogen. The developed advanced 592 
wound dressings were also efficient in eradicating intracellular bacteria. Finally, we have 593 
also demonstrated that the PCL-THY patches were able to remove already formed bacterial 594 
biofilms and also inhibit the first stages of bacterial adhesion and biofilm formation in the 595 
ATCC 25923 and cGFP strains, while the clinical strains biofilms (MSSA Newman and 596 
MRSA USA300) were inhibited at the highest PCL-THY amounts assayed (30 mg). The 597 
developed patches showed cytotoxicity against eukaryotic cells in a dose dependent manner, 598 
but at reduced doses and during short contact times, cell viability was similar to that retrieved 599 
for untreated controls. In this comparative study, research based on evidence demonstrated 600 
that THY-loaded electrospun PCL patches are more efficient that their THY-free 601 
counterparts against pathogenic S. aureus. 602 
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